Targeted killing of colorectal cancer cell lines by a humanised IgG1 monoclonal antibody that binds to membrane-bound carcinoembryonic antigen.

The distribution of carcinoembryonic antigen (CEA) in colorectal cancer (CRC) differs from that in normal colorectal tissue, being found on all borders of the cell membrane and hence enabling access to intravenous antibody, making CEA a good target for antibody-based therapy. The distinctive anti-CE...

Full description

Bibliographic Details
Main Authors: Conaghan, P, Ashraf, S, Tytherleigh, M, Wilding, J, Tchilian, E, Bicknell, D, Mortensen, N, Bodmer, W
Format: Journal article
Language:English
Published: 2008
_version_ 1826271487126929408
author Conaghan, P
Ashraf, S
Tytherleigh, M
Wilding, J
Tchilian, E
Bicknell, D
Mortensen, N
Bodmer, W
author_facet Conaghan, P
Ashraf, S
Tytherleigh, M
Wilding, J
Tchilian, E
Bicknell, D
Mortensen, N
Bodmer, W
author_sort Conaghan, P
collection OXFORD
description The distribution of carcinoembryonic antigen (CEA) in colorectal cancer (CRC) differs from that in normal colorectal tissue, being found on all borders of the cell membrane and hence enabling access to intravenous antibody, making CEA a good target for antibody-based therapy. The distinctive anti-CEA antibody, PR1A3, binds only membrane-bound CEA. Humanised PR1A3 (hPR1A3) was assessed both in vitro cytotoxicity and binding assays with colorectal cancer cell lines expressing varying levels of CEA. Human peripheral blood mononuclear cells (PBMCs) and purified natural killer (NK) cells were used as effectors. The in vitro assays demonstrated hPR1A3 CEA-specific binding and antibody-dependent and CEA-specific killing of human colorectal cancer cell lines by human PBMCs. The effect increased with increasing concentration of antibody and surface CEA, and was lost by using the parent murine IgG1 PR1A3. Killing was also blocked by antibody to the Fc-gammaIIIA receptor. Purified human NK cells were effective at much lower effector:target ratios than unfractionated PBMCs, indicating that NK cells were the main mediators of hPR1A3-based CEA-specific killing. The results support the development of hPR1A3 for therapy of colorectal cancer.
first_indexed 2024-03-06T21:57:25Z
format Journal article
id oxford-uuid:4d641dbe-75c5-4a62-a5ff-ad5ab4539742
institution University of Oxford
language English
last_indexed 2024-03-06T21:57:25Z
publishDate 2008
record_format dspace
spelling oxford-uuid:4d641dbe-75c5-4a62-a5ff-ad5ab45397422022-03-26T15:55:17ZTargeted killing of colorectal cancer cell lines by a humanised IgG1 monoclonal antibody that binds to membrane-bound carcinoembryonic antigen.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:4d641dbe-75c5-4a62-a5ff-ad5ab4539742EnglishSymplectic Elements at Oxford2008Conaghan, PAshraf, STytherleigh, MWilding, JTchilian, EBicknell, DMortensen, NBodmer, WThe distribution of carcinoembryonic antigen (CEA) in colorectal cancer (CRC) differs from that in normal colorectal tissue, being found on all borders of the cell membrane and hence enabling access to intravenous antibody, making CEA a good target for antibody-based therapy. The distinctive anti-CEA antibody, PR1A3, binds only membrane-bound CEA. Humanised PR1A3 (hPR1A3) was assessed both in vitro cytotoxicity and binding assays with colorectal cancer cell lines expressing varying levels of CEA. Human peripheral blood mononuclear cells (PBMCs) and purified natural killer (NK) cells were used as effectors. The in vitro assays demonstrated hPR1A3 CEA-specific binding and antibody-dependent and CEA-specific killing of human colorectal cancer cell lines by human PBMCs. The effect increased with increasing concentration of antibody and surface CEA, and was lost by using the parent murine IgG1 PR1A3. Killing was also blocked by antibody to the Fc-gammaIIIA receptor. Purified human NK cells were effective at much lower effector:target ratios than unfractionated PBMCs, indicating that NK cells were the main mediators of hPR1A3-based CEA-specific killing. The results support the development of hPR1A3 for therapy of colorectal cancer.
spellingShingle Conaghan, P
Ashraf, S
Tytherleigh, M
Wilding, J
Tchilian, E
Bicknell, D
Mortensen, N
Bodmer, W
Targeted killing of colorectal cancer cell lines by a humanised IgG1 monoclonal antibody that binds to membrane-bound carcinoembryonic antigen.
title Targeted killing of colorectal cancer cell lines by a humanised IgG1 monoclonal antibody that binds to membrane-bound carcinoembryonic antigen.
title_full Targeted killing of colorectal cancer cell lines by a humanised IgG1 monoclonal antibody that binds to membrane-bound carcinoembryonic antigen.
title_fullStr Targeted killing of colorectal cancer cell lines by a humanised IgG1 monoclonal antibody that binds to membrane-bound carcinoembryonic antigen.
title_full_unstemmed Targeted killing of colorectal cancer cell lines by a humanised IgG1 monoclonal antibody that binds to membrane-bound carcinoembryonic antigen.
title_short Targeted killing of colorectal cancer cell lines by a humanised IgG1 monoclonal antibody that binds to membrane-bound carcinoembryonic antigen.
title_sort targeted killing of colorectal cancer cell lines by a humanised igg1 monoclonal antibody that binds to membrane bound carcinoembryonic antigen
work_keys_str_mv AT conaghanp targetedkillingofcolorectalcancercelllinesbyahumanisedigg1monoclonalantibodythatbindstomembraneboundcarcinoembryonicantigen
AT ashrafs targetedkillingofcolorectalcancercelllinesbyahumanisedigg1monoclonalantibodythatbindstomembraneboundcarcinoembryonicantigen
AT tytherleighm targetedkillingofcolorectalcancercelllinesbyahumanisedigg1monoclonalantibodythatbindstomembraneboundcarcinoembryonicantigen
AT wildingj targetedkillingofcolorectalcancercelllinesbyahumanisedigg1monoclonalantibodythatbindstomembraneboundcarcinoembryonicantigen
AT tchiliane targetedkillingofcolorectalcancercelllinesbyahumanisedigg1monoclonalantibodythatbindstomembraneboundcarcinoembryonicantigen
AT bicknelld targetedkillingofcolorectalcancercelllinesbyahumanisedigg1monoclonalantibodythatbindstomembraneboundcarcinoembryonicantigen
AT mortensenn targetedkillingofcolorectalcancercelllinesbyahumanisedigg1monoclonalantibodythatbindstomembraneboundcarcinoembryonicantigen
AT bodmerw targetedkillingofcolorectalcancercelllinesbyahumanisedigg1monoclonalantibodythatbindstomembraneboundcarcinoembryonicantigen